MARKET

NVCR

NVCR

Novocure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

128.45
-4.80
-3.60%
Opening 14:00 03/05 EST
OPEN
131.53
PREV CLOSE
133.25
HIGH
133.74
LOW
117.58
VOLUME
873.88K
TURNOVER
--
52 WEEK HIGH
194.75
52 WEEK LOW
53.40
MARKET CAP
13.15B
P/E (TTM)
1789.02
1D
5D
1M
3M
1Y
5Y
Current Sensor Market Technological Trends and Business Opportunities 2021 To 2025; STMicroelectronics N.V. (NYSE: STM), ROHM Co., Ltd. (OTC: ROHCY)
Market Insight Reports · 2d ago
The Global Spintronics Market was valued at USD 303.8 million in 2020, and it is projected to be worth USD 4,558.5 million by 2026, registering a CAGR of 50.4%, during the period 2021-2026
New York, March 02, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, March 02, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 3d ago
DJ Novocure Is Maintained at Buy by Mizuho
Dow Jones · 4d ago
DJ Novocure Price Target Raised to $175.00/Share From $150.00 by Mizuho
Dow Jones · 4d ago
--Analyst Actions: Mizuho Adjusts Price Target on NovoCure to $175 From $150, Maintains Buy Rating
MT Newswires · 4d ago
Spintronics Market : Analysis and In-depth Study on Size Trends, Emerging Growth Factors and Regional Forecast to 2025
Japan, Japan, Mon, 01 Mar 2021 01:57:53 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 4d ago
Selling Before NVCR Stock Earnings Captured Quick Gain
Between earnings and a market pullback, this week hasn't been easy. But reducing exposure helped protect our gains.
Investor's Business Daily · 6d ago
NovoCure (NVCR) Receives a Buy from Northland Securities
Northland Securities analyst Jason Wittes maintained a Buy rating on NovoCure (NVCR) today and set a price target of $200.00. The company's shares closed
SmarterAnalyst · 02/26 18:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVCR. Analyze the recent business situations of Novocure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVCR stock price target is 154.88 with a high estimate of 225.00 and a low estimate of 103.00.
EPS
Institutional Holdings
Institutions: 517
Institutional Holdings: 75.80M
% Owned: 74.01%
Shares Outstanding: 102.41M
TypeInstitutionsShares
Increased
118
5.68M
New
136
-622.21K
Decreased
84
4.07M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.66%
Healthcare Equipment & Supplies
+1.12%
Key Executives
Chairman/Executive Director
William Doyle
President/Chief Executive Officer/Director
Asaf Danziger
Vice Chairman/Director
Gabriel Leung
Chief Financial Officer
Ashley Cordova
Corporate Executive
Ely Benaim
Chief Operating Officer
Wilhelmus Groenhuysen
Vice President
Michael Ambrogi
General Counsel
Todd Longsworth
Other
Frank Leonard
Other
Pritesh Shah
Lead Director/Independent Director
William Vernon
Independent Director
Kinyip Leung
Director
Timothy Scannell
Independent Director
Jeryl Hilleman
Independent Director
David Hung
Independent Director
Kinyip Gabriel Leung
Independent Director
Martin Madden
Independent Director
Sherilyn McCoy
No Data
  • All
  • Financials
  • Insiders
More
About NVCR
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Webull offers kinds of Novocure Ltd stock information, including NASDAQ:NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.